ArticleDiagnostic pathology2012
Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma.
Article in Diagnostic pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Transcriptomics analysis identified ezrin as a potential druggable target in cervical and gastric cancer cells.Clinics (Sao Paulo, Brazil) · 2024Article
- Upregulation of the oestrogen target gene SIX1 is associated with higher growth speed and decreased survival in HCV-positive women with hepatocellular carcinoma.Oncology letters · 2022Article
- FIS1 Overexpression Is Correlated with Tumor Metastasis in Gastric Adenocarcinoma.Journal of gastrointestinal cancer · 2022Article
- Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation.International journal of biological sciences · 2022Article
- Immunohistochemical Study of Ezrin Expression in Colorectal Carcinoma: A Comparative Study between Objective Method and Digital Quantitative Assessment.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A Review.Frontiers in cell and developmental biology · 2020Review
- MST4 Predicts Poor Prognosis And Promotes Metastasis By Facilitating Epithelial-Mesenchymal Transition In Gastric Cancer.Cancer management and research · 2019Article
- Ezrin regulates skin fibroblast size/mechanical properties and YAP-dependent proliferation.Journal of cell communication and signaling · 2018Article
- Molecular background of the regional lymph node metastasis of gastric cancer.Oncology letters · 2018Review
- Association of Ezrin expression with the progression and prognosis of gastrointestinal cancer: a meta-analysis.Oncotarget · 2017Article
- Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.International journal of clinical and experimental pathology · 2015Article
- Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patients.Molecular and clinical oncology · 2014Article
- Article
- High expression of DEK predicts poor prognosis of gastric adenocarcinoma.Diagnostic pathology · 2014Article
- The expression and clinical significance of miR-132 in gastric cancer patients.Diagnostic pathology · 2014Article
- Activation of P21-activated protein kinase 2 is an independent prognostic predictor for patients with gastric cancer.Diagnostic pathology · 2014Article
- Clinical implications of high NQO1 expression in breast cancers.Journal of experimental & clinical cancer research : CR · 2014Article
- Overexpression of sineoculis homeobox homolog 1 predicts poor prognosis of hepatocellular carcinoma.International journal of clinical and experimental pathology · 2014Article
- Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis.International journal of clinical and experimental pathology · 2014Article
- Radixin enhances colon cancer cell invasion by increasing MMP-7 production via Rac1-ERK pathway.TheScientificWorldJournal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEzrin is a cytoskeletal protein that is involved in tumor growth and invasion. It has been suggested that Ezrin expression plays an important role in tumor metastasis. This study is aimed to investigate the clinicopathological significance of Ezrin overexpression in gastric adenocarcinomas.
methodsEzrin protein expression was examined by immunohistochemistry in 26 normal gastric mucosa, 32 dysplasia, and 277 gastric adenocarcinomas. The relationship between Ezrin expression and the clinicopathological features of gastric cancers was analyzed. In addition, a gastric cancer cell line, MKN-1, was also used for immunofluorescence staining to evaluate the distribution of Ezrin protein.
resultsEzrin protein located in the cytoplasm and/or membrane in the migrating gastric cancer cells, and it mainly concentrated at the protrusion site; however, only cytoplasmic distribution was observed in the non-migrating cancer cells by immunofluorescence staining. The positive rate of Ezrin protein expression was significantly higher in gastric adenocarcinoma and dysplasia compared with that in the normal gastric mucosa. Moreover, expression frequency of Ezrin protein increased significantly in lymph node metastasis and late clinical stages. Consistently, strong expression of Ezrin was significantly correlated with poor prognosis of gastric cancer.
conclusionThe detection of Ezrin expression can be used as the marker for early diagnosis and prognosis of gastric adenocarcinoma. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2303598677653946.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.